Abstract: The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof, for use for preventing and/or treating disorders associated with cellular necroptosis. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

Abstract: The present invention relates to nucleic acids, compositions and methods for the treatment of facioscapulohumeral dystrophy.

Abstract: The present invention relates to the use of a homeoprotein or a recombinant vector encoding said protein for treating or preventing DNA damage and/or cellular aging. In particular, the invention concerns the use of Engrailed for the treatment of Parkinson disease.

Abstract: The present invention relates to the use of interleukin-2 (IL-2) for treating a food allergy, either by inducing non-specific tolerance against food allergens, or in a desensitization protocol in combination with a food allergen.

Abstract: Inventors have shown that the protein isthmin-1 (ISM-1) is expressed at kidney level in animal and human model. They have also shown that this protein is expressed on the surface but also intracellular of the circulating leukocytes. They have observed that its expression is increased when a subject suffers from INS, MCN or FSGS compared to healthy controls. Among various causes of nephrotic syndrome, ISM-1 leucocyte expression is dramatically increased in patients with INS, MCN or FSGS. Accordingly, the present invention relates to a method for diagnosing INS, MCN or FSGS in a subject comprising the steps of: i) measuring the membrane expression level of isthmin-1 on the circulating leukocytes in a biological sample obtained from said subject; ii) comparing the expression level measured at step i) with its predetermined reference value, and iii) concluding that the subject suffers from INS, MCN or FSGS when the membrane expression level of isthmin-1 is higher than its predetermined reference value.

Abstract: The present invention relates to a method to analyse the ability of a substance (3) to cross a bilayer membrane comprising the following steps: (i) providing in a hydrophobic medium (1) a first droplet D1 of an aqueous solution AS1, wherein the droplet D1 is surrounded by a monolayer of amphiphilic molecules (2), (ii) providing in the said hydrophobic medium (1) a second droplet D2 of an aqueous solution AS2 containing the substance (3) to be analysed, wherein the droplet D2 is surrounded by a monolayer of amphiphilic molecules (2), (iii) putting the first droplet D1 and the second droplet D2 into contact so as to form a bilayer of amphiphilic molecules (2) in the contact area and to have a contact angle 2? between the two droplets D1 and D2 comprised between 10° and 180°, (iv) adding to the hydrophobic medium (1) a solvent capable of separating the droplets D1 and D2 put into contact, (v) collecting the droplet D1, and (vi) analysing the content of the droplet D1 in order to determine the presence or not of

Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.

Abstract: A transparent photorechargeable electrochemical device is provided. An n-type semiconductor may be used as a positive-electrode active material in the transparent photorechargeable electrochemical device. A method for photorecharging the device is also provided.

Abstract: Methods for the diagnosis and prognosis of neurodegenerative diseases, such as Alzheimer's disease, are described. Compositions and method for the treatment of neurodegenerative diseases are also described.

Abstract: The invention concerns a device 10 for illuminating an object 12 with a controlled light intensity, the light intensity being controlled when the light intensity fulfills a plurality of conditions to be fulfilled, the plurality of conditions comprising a condition relative to the intensity at a given time and a condition relative to the dose during a period of time.

Abstract: The invention relates to a novel olfactory/pheromonal receptor (SlitOR5) of Spodoptera littoralis (Lepidoptera, Noctuidae) and the identification of the natural ligand of Slit OR5 and uses thereof.

Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

Abstract: The present invention relates to cyclic peptides mimetics of the C-terminal binding domain of TSP-1. The present invention also relates to the use of these cyclic peptides as agonists of CD47 and their ability to trigger programmed cell death (PCD). The present invention further relate to a pharmaceutical composition for use in the treatment of diseases associated with defects in PCD such as cancers and immunological disorders (including chronic inflammation) and comprising at least one cyclic peptide according to the invention.

Abstract: Provided herein is a method for synthesizing polynucleic acids, comprising the steps of (a) providing an acidic solution substantially free of nucleic acid polymerase and lipids, but containing mononucleotides and a monovalent salt; (b) drying and resolubilizing the mixture of step (a) a plurality of times; and (c) recovering polynucleic acids from a resolubilized mixture of step (b). In certain aspects, the method further uses a low pH, e.g. about 3; it can utilize monophosphates, such as AMP rather than ATP; and it can be used with a polynucleotide template to form a sequence at least partially complementary to said template. Thus, both single-stranded and double-stranded polynucleic acids are provided. Ammonia salts have been used to obtain RNA lengths from 10 to 300 nucleotides after 16 half hour cycles and an effective temperature includes between 80° C. and 100° C.

Abstract: Method for visual tracking of at least one object represented by a cluster of points with which information is associated, characterised in that it includes steps to: receive (E1) data representing a set of space-time events, determine (E2) the probability that an event in the set belongs to the cluster of points representing the at least one object, for each event in the received set, determine (E3) whether or not an event belongs to the cluster of points as a function of the determined probability for the event considered, for each event in the received set, update (E4) information associated with the cluster of points for at least one object, for each event for which it was determined in the previous step that it belongs to the cluster of points, calculate (E4, E5) the position, size and orientation of the at least one object as a function of the updated information.

Abstract: The invention relates to a photoreceptor device, with a first crystalline, semi-conductive material, comprising a first lattice parameter, and a second crystalline, semi-conductive material, deposited on the first material and comprising a second lattice parameter, different from the first lattice parameter. In particular, the device comprises an interface layer between the first and second materials, made from an amorphous material and structured to comprise regularly spaced apart openings in the plane of the layer. The second material comprises protuberances coming out of the openings of the interface layer and forming separated crystal grains, each grain comprising a plurality of facets forming at least one angle relative to one another.

Abstract: The disclosed method includes, from a topographic map showing, for a set of points {x} located in a midplane of the fracture surface, a height of the fracture surface h relative to the midplane: a step of determining, for each point x on the topographic map, a quantity ?? representative of an average difference in height)I?xI?? between the height h of the fracture surface at point x in question and the height h of the fracture surface at one or more points {x+?x} located inside a circle of radius ? centered on point x in question, a step of determining, according to a test distance ?r, a spatial correlation function C? representing a spatial correlation between points {x} and points {x+?x} such as I?xI=?r, and a step of determining a correlation length ? from the spatial correlation function C?.

Abstract: Electroacoustic device having a transducer including a piezoelectric substrate, first and second electrodes of inverse polarity having respective first and second tracks provided on said substrate, the first and second tracks spiraling around a same center (C), the transducer being configured for generating a swirling ultrasonic surface wave in the substrate.

Abstract: The invention relates to compounds of formula (I), particularly for the use thereof as a medicament, especially in the treatment or prevention of neurogenerative disorders. The invention also relates to the methods for producing said compounds, and to the pharmaceutical compositions containing same.

Abstract: The invention relates to the use of interleukin-2 in treating spondyloarthritis in a human subject, wherein IL-2 is to be administered at a dose of about I to about 2 MIU/day, wherein the treatment comprises at least a first course wherein interleukin-2 is administered once per day during at least 3 consecutive days, followed by a maintenance treatment after 1 to 4 weeks.